FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Jordan

Research Profile

Chemicals & Drugs

Physiology

Procedures

Living Beings

Macaca fascicularis

Concepts & Ideas

Disorders

Coronary Disease

Devices

Stents

Anatomy

Co-author Network

Publications

TOP 3
Dora Berman-Weinberg; Over Cabrera; Norman M Kenyon; Joshua Miller; Susan H Tam; Vrinda S Khandekar; Kristen M Picha; Avery R Soderman; Robert E Jordan; Peter J Bugelski; Denison Horninger; Michael Lark; Janet E Davis; Rodolfo Alejandro; Per-Olof Berggren; Mark Zimmerman; John J O'Neil; Camillo Ricordi; Norma S Kenyon
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model.
David M Knight; Robert E Jordan; Marian Kruszynski; Susan H Tam; Jill Giles-Komar; George Treacy; George A Heavner
Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by site-specific pegylation.
Marian T Nakada; Michael O Montgomery; Mark A Nedelman; J Luis Guerrero; Sidney A Cohen; Elliot S Barnathan; Robert E Jordan
Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Jordan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Dora Berman-Weinberg; Over Cabrera; Norman M Kenyon; Joshua Miller; Susan H Tam; Vrinda S Khandekar; Kristen M Picha; Avery R Soderman; Robert E Jordan; Peter J Bugelski; Denison Horninger; Michael Lark; Janet E Davis; Rodolfo Alejandro; Per-Olof Berggren; Mark Zimmerman; John J O'Neil; Camillo Ricordi; Norma S Kenyon
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model.
Transplantation 2007;84(3):308-15.
2004: David M Knight; Robert E Jordan; Marian Kruszynski; Susan H Tam; Jill Giles-Komar; George Treacy; George A Heavner
Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by site-specific pegylation.
Platelets 2004;15(7):409-18.
2004: Marian T Nakada; Michael O Montgomery; Mark A Nedelman; J Luis Guerrero; Sidney A Cohen; Elliot S Barnathan; Robert E Jordan
Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
Journal of vascular and interventional radiology : JVIR 2004;15(2 Pt 1):169-76.
2002: Marian T Nakada; Patricia M Sassoli; Susan H Tam; Mark A Nedelman; Robert E Jordan; Dean J Kereiakes
Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
Journal of thrombosis and thrombolysis 2002;14(1):15-24.
2002: Tullio Palmerini; Mark A Nedelman; Lesley E Scudder; Marian T Nakada; Robert E Jordan; Susan Smyth; Ronald E Gordon; John T Fallon; Barry S Coller
Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates.
Journal of the American College of Cardiology 2002;40(2):360-6.
2002: Stanley J Marciniak; Mary Ann Mascelli; Mark I Furman; Alan D Michelson; Joseph A Jakubowski; Robert E Jordan; Peter J Marchese; Andrew L Frelinger
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Thrombosis and haemostasis 2002;87(6):1020-5.
2002: Jane Freedman; Mary Ann Mascelli; John C Pezzullo; Elliot S Barnathan; Bart Frederick; Robert E Jordan; Darrell R. Abernethy
Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.
American heart journal 2002;143(1):87-94.
2001: James E Tcheng; Dean J Kereiakes; A Michael Lincoff; Barry S George; Neal S Kleiman; David C Sane; Douglas B Cines; Robert E Jordan; Mary Ann Mascelli; Mary Ann Langrall; Lakshmi V Damaraju; A Schantz; Mark B Effron; Gregory A Braden
Abciximab readministration: results of the ReoPro Readministration Registry.
Circulation 2001;104(8):870-5.
2001: Patricia M Sassoli; Eva Emmell; Susan H Tam; Mohit Trikha; Zhao Zhou; Robert E Jordan; Marian T Nakada
7E3 F(ab')2, an effective antagonist of rat alphaIIbbeta3 and alphavbeta3, blocks in vivo thrombus formation and in vitro angiogenesis.
Thrombosis and haemostasis 2001;85(5):896-902.
2001: Stanley J Marciniak; Robert E Jordan; Mary Ann Mascelli
Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Thrombosis and haemostasis 2001;85(3):539-43.
2000: Neal S Kleiman; N Grazeiadei; Kelly Maresh; R J Taylor; Bart Frederick; ET Lance; Mark B Effron; Robert E Jordan; Mary Ann Mascelli
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
American heart journal 2000;140(3):492-501.
2000: Mary Ann Mascelli; Neal S Kleiman; Stanley J Marciniak; Lakshmi V Damaraju; HF Weisman; Robert E Jordan
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
American heart journal 2000;139(4):696-703.
2000: Neal S Kleiman; N Graziadei; Robert E Jordan; ET Lance; A Fischer; Kelly Maresh; A Edwards; Mary Ann Mascelli
Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro.
Journal of thrombosis and thrombolysis 2000;9(1):29-36.
1999: James E Tcheng; Dean J Kereiakes; Gregory A Braden; Robert E Jordan; Mary Ann Mascelli; Mary Ann Langrall; Mark B Effron
Readministration of abciximab: interim report of the ReoPro readministration registry.
American heart journal 1999;138(1 Pt 2):S33-8.
1999: J A Varner; Marian T Nakada; Robert E Jordan; Barry S Coller
Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro).
Angiogenesis 1999;3(1):53-60.
1998: Jonathan S Deitch; J Koudy Williams; Michael R Adams; Christopher A Fly; David M Herrington; Robert E Jordan; Marian T Nakada; J A Jakubowski; Randolph L Geary
Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(11):1730-7.
1998: Susan H Tam; Patricia M Sassoli; Robert E Jordan; Marian T Nakada
Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
Circulation 1998;98(11):1085-91.
1998: Mary Ann Mascelli; ET Lance; Lakshmi V Damaraju; C L Wagner; HF Weisman; Robert E Jordan
Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
Circulation 1998;97(17):1680-8.
1997: Mary Ann Mascelli; S Worley; N J Veriabo; ET Lance; S Mack; Thomas Schaible; HF Weisman; Robert E Jordan
Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
Circulation 1997;96(11):3860-6.
1996: C L Wagner; Mary Ann Mascelli; D S Neblock; HF Weisman; Barry S Coller; Robert E Jordan
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.
Blood 1996;88(3):907-14.